Fig. 6

Effect of BSTL on mitochondrial biogenesis and dysfunction in vitro. A Immunofluorescence results of TOM20 in podocytes from different groups (× 400). Scale bar, 30 µm. B Immunofluorescence results of MitoTracker in podocytes from different groups (× 400). Scale bar, 30 µm. C Quantitation of mtDNA content in podocytes from different groups. D Quantitation of mitochondrial respiratory chain complexes I, III, and IV activities in podocytes from different groups. E Representative western blots and quantitative assessment of PGC-1α, MFN2, DRP1, and TFAM in podocytes from different groups. F Representative flow cytometry analysis depicting the detection of MMP in podocytes with different treatments, and quantitative data expressing the overall percentage of cells apoptotic and necrotic (Q2 represented the ratio of red fluorescence, Q3 represented the ratio of green fluorescence, Q2/Q3 represented the MMP). G Representative flow cytometry scatter plots and quantitative assessment of ROS production in podocytes from different groups. ^*P < 0.05 vs. NG; ^**P < 0.01 vs. NG; ^#P < 0.05 vs. HG; ^##P < 0.01 vs. HG. NG, normal glucose; HG, high glucose; HG + B, high glucose combined with BSTL drug-containing serum